- Thomas, Nancy E;
- Edmiston, Sharon N;
- Orlow, Irene;
- Kanetsky, Peter A;
- Luo, Li;
- Gibbs, David C;
- Parrish, Eloise A;
- Hao, Honglin;
- Busam, Klaus J;
- Armstrong, Bruce K;
- Kricker, Anne;
- Cust, Anne E;
- Anton-Culver, Hoda;
- Gruber, Stephen B;
- Gallagher, Richard P;
- Zanetti, Roberto;
- Rosso, Stefano;
- Sacchetto, Lidia;
- Dwyer, Terence;
- Ollila, David W;
- Begg, Colin B;
- Berwick, Marianne;
- Conway, Kathleen;
- Berwick, Marianne;
- Begg, Colin;
- Orlow, Irene;
- Busam, Klaus J;
- Roy, Pampa;
- Reiner, Anne;
- Leong, Siok;
- Guerrero, Sergio Corrales;
- Sadeghi, Keimya;
- Berwick, Marianne;
- Luo, Li;
- Boyce, Tawny W;
- Cust, Anne E;
- Armstrong, Bruce K;
- Kricker, Anne;
- Venn, Alison;
- Dwyer, Terence;
- Tucker, Paul;
- Gallagher, Richard P;
- Marrett, Loraine D;
- From, Lynn;
- Zanetti, Roberto;
- Rosso, Stefano;
- Anton-Culver, Hoda;
- Gruber, Stephen B;
- Huang, Shu-Chen;
- Thomas, Nancy E;
- Conway, Kathleen;
- Ollila, David W;
- Groben, Pamela A;
- Edmiston, Sharon N;
- Hao, Honglin;
- Parrish, Eloise;
- Frank, Jill S;
- Gibbs, David C;
- Rebbeck, Timothy R;
- Kanetsky, Peter A;
- Taylor, Julia Lee;
- Madronich, Sasha
BRAF and NRAS mutations arise early in melanoma development, but their associations with low-penetrance melanoma susceptibility loci remain unknown. In the Genes, Environment and Melanoma Study, 1,223 European-origin participants had their incident invasive primary melanomas screened for BRAF/NRAS mutations and germline DNA genotyped for 47 single-nucleotide polymorphisms identified as low-penetrant melanoma-risk variants. We used multinomial logistic regression to simultaneously examine each single-nucleotide polymorphism's relationship to BRAF V600E, BRAF V600K, BRAF other, and NRAS+ relative to BRAF-/NRAS- melanoma adjusted for study features. IRF4 rs12203592*T was associated with BRAF V600E (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.43-0.79) and V600K (OR = 0.65, 95% CI = 0.41-1.03), but not BRAF other or NRAS+ melanoma. A global test of etiologic heterogeneity (Pglobal = 0.001) passed false discovery (Pglobal = 0.0026). PLA2G6 rs132985*T was associated with BRAF V600E (OR = 1.32, 95% CI = 1.05-1.67) and BRAF other (OR = 1.82, 95% CI = 1.11-2.98), but not BRAF V600K or NRAS+ melanoma. The test for etiologic heterogeneity (Pglobal) was 0.005. The IRF4 rs12203592 associations were slightly attenuated after adjustment for melanoma-risk phenotypes. The PLA2G6 rs132985 associations were independent of phenotypes. IRF4 and PLA2G6 inherited genotypes may influence melanoma BRAF/NRAS subtype development.